Nanoform 1Q 2022 report: Quarterly record of new projects and new customers
HELSINKI, May 24, 2022 /PRNewswire/ -- The positive momentum continues. A quarterly record of eight new non-GMP projects with seven different customers signed. Revenue grew by 174%, the number of employees by 49%, while the total operating costs grew by 27%. The gross margin rose to 92%. Signific...
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
HELSINKI, Finland, March 23, 2022 /PRNewswire/ -- Inside information Nanoform Finland Plc March 22, 2022 23:45 Finnish time / 22:45 Swedish time Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in theUSA NOT FOR RELEASE, PUBLICATION OR D...
Nanoform and Boehringer Ingelheim execute master services agreement
HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...
Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time
HELSINKI, Nov. 27, 2020 /PRNewswire/ -- Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, on...
